News

In a Yale study, researchers found that seven-day injectable buprenorphine and daily tablet buprenorphine are equally safe and effective in engaging patients with opioid use disorder in treatment after an emergency department visit.

A team of researchers at Yale School of Medicine (YSM) is helping determine risks and benefits for higher-than-previously recommended doses of a medication to treat opioid use disorder.

A recent study conducted by Yale researchers focused on the intersection of unhealthy alcohol use and adherence to pre-exposure prophylaxis (PrEP) among gay, bisexual, and other men who have sex with men. The research, undertaken between February 2019 and July 2020, involved semi-structured interviews with 15 men who have sex with men in Providence, Rhode Island and New Haven, Connecticut, who were prescribed PrEP and had screened positive for unhealthy alcohol use.

Yale-led study sheds light on additional health threats beyond the well-documented consequences of the opioid crisis.

A new Yale-led project seeks to study treatment retention for women facing intimate partner violence and opioid use disorder.